NeuroPace, Inc.

While investors and executives in the health care products industry have not remained untouched by the COVID-19 pandemic, they have not been as surprised as people might assume about the situation tha

NeuroPace has secured $67m to accelerate the commercialization of its RNS implantable brain stimulator for the treatment of medication-refractory focal epilepsy. The funding will also help the compan

The venture financing climate in 2017 has proven to be more favorable than in 2016, after October's total takings of $295.1m pushed the year's total deal value to date to $5.28bn, surpassing 2016's $5

Last month in the first of a two-part series, START-UP provided a top-level view of investments in private CNS companies across biopharma, medtech and diagnostics firms from 2010 through July 2015 u